Axsome Therapeutics is trading at $152.30, up 5.45%, ahead of Q3 2026 earnings as investors watch Auvelity’s launch and commercial trajectory in Alzheimer’s agitation.
- Q3 2026 earnings are scheduled before the market open on November 2.
- Analysts estimate revenue of $249.19 million and an EPS loss of $0.68; these are estimates, not reported results.
- Major U.S. indices are also higher, though no source confirms that market context drove the move.